	US 12,221,464 B2
	Methods of treatment of IL-17A associated conditions
Fredrik Frejd, Stockholm (SE); Joachim Feldwisch, Tyresö (SE); Susanne Klint, Stockholm (SE); and Lindvi Gudmundsdotter, Stockholm (SE)
Assigned to AFFIBODY AB, Solna (SE)
Filed by AFFIBODY AB, Solna (SE)
Filed on Feb. 1, 2021, as Appl. No. 17/163,961.
Application 17/163,961 is a continuation of application No. 15/538,890, granted, now 10,934,335, previously published as PCT/EP2016/050456, filed on Jan. 12, 2016.
Claims priority of application No. 15150786 (EP), filed on Jan. 12, 2015.
Prior Publication US 2021/0253659 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/20 (2006.01); C07K 14/54 (2006.01); C07K 14/745 (2006.01)

CPC C07K 14/54 (2013.01) [A61K 38/20 (2013.01); C07K 14/745 (2013.01); A61K 38/00 (2013.01); C07K 2318/20 (2013.01)]

32 Claims

1. A method of treatment of an IL-17A associated condition, comprising administering to a subject in need thereof an IL-17A binding polypeptide,

wherein said IL-17A binding polypeptide comprises an IL-17A binding motif BM, which motif consists of an amino acid sequence selected from:

i) EX₂DX₄AX₆X₇EIX₁₀X₁₁LPNL X₁₆X₁₇X₁₈QX₂₀X₂₁AFIX₂₅X₂₆LX₂₈X₂₉(SEQ ID NO: 1295)

wherein, independently from each other,

X₂is selected from A, H, M and Y;

X₄is selected from A, D, E, F, K, L, M, N, Q, R, S and Y;

X₆is selected from A, Q and W;

X₇is selected from F, I, L, M, V, W and Y;

X₁₀is selected from A and W;

X₁₁is selected from A, D, E, F, G, L, M, N, Q, S, T and Y;

X₁₆is selected from N and T;

X₁₇is selected from H, W and Y;

X₁₈is selected from A, D, E, H and V;

X₂₀is selected from A, G, Q, S and W;

X₂₁is selected from A, D, E, F, H, K, N, R, T, V, W and Y;

X₂₅is selected from A, D, E, G, H, I, L, M, N, Q, R, S, T and V;

X₂₆is selected from K and S;

X₂₈is selected from I, L, N and R; and

X₂₉is selected from D and R;

and

ii) an amino acid sequence which has at least 96% identity to the sequence defined in i).